Search Results - "Oleksii, Kolesnik"

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer by Janjigian, Yelena Y., Kawazoe, Akihito, Yañez, Patricio, Li, Ning, Lonardi, Sara, Kolesnik, Oleksii, Barajas, Olga, Bai, Yuxian, Shen, Lin, Tang, Yong, Wyrwicz, Lucjan S., Xu, Jianming, Shitara, Kohei, Qin, Shukui, Van Cutsem, Eric, Tabernero, Josep, Li, Lie, Shah, Sukrut, Bhagia, Pooja, Chung, Hyun Cheol

“…Human epidermal growth factor receptor 2 ( HER2 , also known as ERBB2 ) amplification or overexpression occurs in approximately 20% of advanced gastric or…”
Get full text

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study by Tokito, Takaaki, Kolesnik, Oleksii, Sørensen, Jens, Artac, Mehmet, Quintela, Martín Lázaro, Lee, Jong-Seok, Hussein, Maen, Pless, Miklos, Paz-Ares, Luis, Leopold, Lance, Daniel, Jeannie, Munteanu, Mihaela, Samkari, Ayman, Xu, Lu, Butts, Charles

“…Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other…”
Get full text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial by Paz-Ares, Luis, Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Hochmair, Maximilian J, Özgüroğlu, Mustafa, Ji, Jun Ho, Bondarenko, Igor, Byrne, Natalie, Shire, Norah, Goldman, Jonathan W, Batagelj, Emilio, Casarini, Ignacio, Pastor, Anea Viviana, Hartl, Sylvia, Hochmair, Maximilian J, Lamprecht, Bernd, Dos Reis, Peo, Serodio da Rocha Baldotto, Clarissa, Venkova, Violetka, Bi, Minghong, Chen, Zhendong, Han, Zhigang, Hu, Yi, Li, Wei, Ma, Shenglin, Nan, Kejun, Shu, Yongqian, Wang, Kai, Yang, Nong, Zhang, Wei, Zhao, Jun, Zhao, Yanqiu, Zhou, Caicun, Zhou, Xiangdong, Skrickova, Jana, Hilgers, Werner, Moro-Sibilot, Denis, Bischoff, Helge, Lang, Susanne, Fülöp, Anea, Horváth, Zsolt, Laczó, Ibolya, Losonczy, György, Pápai Székely, Zsolt, Telekes, Anás, Bar, Jair, Gottfried, Maya, Heching, Norman Isaac, Bettini, Anna Cecilia, Minelli, Mauro, Roila, Fausto, Verderame, Francesco, Atagi, Shinji, Goto, Hisatsugu, Goto, Koichi, Hara, Yu, Hida, Toyoaki, Hotta, Katsuyuki, Kuyama, Shoichi, Morise, Masahiro, Nakahara, Yasuharu, Okamoto, Isamu, Shinoda, Masahiro, Umemura, Shigeki, Heniks, Lizza, Ungureanu, Anei, Luft, Alexander, Sakaeva, Dina, Smolin, Alexey, Statsenko, Galina, Vasilyev, Alexander, Vladimirova, Lyubov, Chovanec, Jozef, Urda, Michal, Ji, Jun Ho, Lee, Kyung Hee, Isla Casado, Dolores, Ponce Aix, Santiago, Hsia, Te-Chun, Wu, Shang-Yin, Çiçin, Irfan, Göksel, Tuncay, Özgüroğlu, Mustafa, Adamchuk, Hryhoriy, Bondarenko, Igor, Kryzhanivska, Anna, Shevnia, Serhii, Trukhin, Dmytro, Ursol, Grygorii, Voitko, Oleksandr, Vynnychenko, Ihor, Chen, Yuanbin, Chua, Winston, Dakhil, Shaker, Goldman, Jonathan W, Lakhanpal, Shailena, Powell, Steven, Stilwill, Joseph

“…Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has…”
Get full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial by Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Özgüroğlu, Mustafa, Ji, Jun Ho, Garassino, Marina Chiara, Poltoratskiy, Artem, Ponce, Santiago, Bondarenko, Igor, Conev, Nikolay V, Armstrong, Jon, Byrne, Natalie, Jiang, Haiyi, Paz-Ares, Luis, Voitko, Nataliia, Poltoratskiy, Artem, Bondarenko, Igor, Chen, Yuanbin, Özgüroglu, Mustafa, Conev, Nikolay, Burghuber, Otto, Moiseenko, Vladimir, Reinmuth, Niels, Ursol, Grygorii, Pajkos, Gábor, Verderame, Francesco, Smolin, Alexey, Göksel, Tuncay, Dakhil, Shaker, Lee, Jong-Seok, Garcia Campelo, Maria Rosario, Alacacioglu, Ahmet, Casarini, Ignacio, Ilieva, Rumyana, Somfay, Attila, Roila, Fausto, Urda, Michal, Majem Tarruella, Margarita, Bettini, Anna Cecilia, Okamoto, Isamu, Mandziuk, Slawomir, Domine Gomez, Manuel, Wu, Shang-Yin, Knoble, Jeanna, Venkova, Violetka, Laack, Eckart, Bischoff, Helge, Fülöp, Andrea, Telekes, András, Kanda, Shintaro, Nakahara, Yasuharu, Lin, Sheng-Hao, Schaefer, Eric, Nikolinakos, Petros, Schneider, Jeffrey, Kultan, Juraj, Kolek, Vitezslav, Lee, Kyung Hee, Goloborodko, Olexandr, Kolesnik, Oleksii, Ostapenko, Yuriy, Stilwill, Joseph, De Marchi, Pedro Rafael Martins, Krasteva, Rositsa, Koubkova, Leona, Grohe, Christian, Heching, Norman Isaac, Harada, Daijiro, Nogami, Naoyuki, Nokihara, Hiroshi, Goto, Hisatsugu, Staal van den Brekel, Agnes, Ganea, Doina, Popova, Ekaterina, Sakaeva, Dina, Stresko, Marian, Demo, Pavol, Hsia, Te-Chun, Lee, Kang-Yun, Zarba, Juan Jose, Pastor, Andrea Viviana, Zukin, Mauro, Calabrich, Aknar, Dudov, Asen, Lang, Susanne, Kanazawa, Kenya, Hiltermann, Jeroen, Shparyk, Yaroslav, Kryzhanivska, Anna, Jamil, Rodney, Williamson, Michael, Han, Zhigang, Wang, Mengzhao, Li, Wei, Feng, Jifeng, Zhou, Xiangdong, Hu, Yi, Nan, Kejun, Zhang, Wei, Lin, Zhong

“…First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus…”
Get full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial by Rha, Sun Young, Oh, Do-Youn, Yañez, Patricio, Bai, Yuxian, Ryu, Min-Hee, Lee, Jeeyun, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Shiu, Kai-Keen, Fernández, Manuel González, Li, Jin, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Qin, Shukui, Luo, Suxia, Pan, Hongming, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, Wyrwicz, Lucjan S

“…PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of…”
Get full text

P-137PROGNOSTIC ROLE OF CLINICO-MORPHOLOGICAL FACTORS by Kolesnik, Oleksii

“…Objectives 30-60% of patients with early stages of non-small cell lung cancer have disease progression after operation. Molecular-genetic markers can help to…”
Get full text

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study by Millan, Susana, Trukhin, Dmytro, Kolesnik, Oleksii, Poddubskaya, Elena, Zoran, Andric, Bondarenko, Igor, Shevnia, Serhii, Bullo, Felicitas, Sarnago, Cristina

“…Abstract only e21542 Background: MB02 is a proposed biosimilar of the reference bevacizumab. A multinational, double-blind, randomized, parallel group clinical…”
Get full text

Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study by Chen, Likun, Trukhin, Dmytro, Kolesnik, Oleksii, Gomez Rangel, Jose David David, Cil, Timucin, Li, Xingya, Cicin, Irfan, Kobziev, Oleh, Shen, Yihong, Liu, Zhihua, Oleksandr, Ivashchuk, Ozyilkan, Ozgur, Igor, Bondarenko, Ursol, Grygorii, Chen, Jun, Oleksandr, Kostiuk, Chen, Zhendong, Zhang, Helong, Tural, Deniz, Zhang, Li

“…9041 Background: A Randomized, Double-blind, Phase III Study was conducted to confirm clinical similarity between BAT1706, a proposed biosimilar to reference…”
Get full text

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial by Wakelee, Heather, Lee, Se-Hoon, Dooms, Christophe, Majem, Margarita, Novello, Silvia, Arunachalam, Ashwini, Keller, Steven M, Gao, Shugeng, Afanasyev, Sergey, Ahmed, Samreen, Alekshun, Todd, Alves, Gustavo, Anderson, Ian, Arkhipov, Alexander, Arora, Arvind, Berceanu-Ion, Radu, Bernabe Caro, Reyes, Bondarenko, Igor, Brocca, Carlos, Bryl, Maciej, Carcereny, Enric, Chaft, Jamie, Chaves, Fabio, Chen, Jun, Chiang, Chi-Lu, Ciurescu, Ioana, Coetzee, Corlia, Collins, Dearbhaile, Costas, Kimberly, Costin, Dan, Cronemberger, Eduardo Henrique, de Paiva Junior, Tadeu, Delmonte, Angelo, Demedts, Ingel, Dooms, Christophe, Dutra, Carolina, Ernani, Vinicius, Faehling, Martin, Ferrara, Roberto, Frohling, Klaus-Peter, Furqan, Muhammad, Gianni, Luca, Gilli, Marina, Goranov, Bojidar, Guarino, Michael, Halmos, Balazs, Ikeda, Norihiko, Intagliata, Salvatore, Jain, Kirti, Karaseva, Nina, Kaywin, Paul, Keresztes, Roger, Kolesnik, Oleksii, Kristedja, Timothy, Levenko, Oleh, Li, Shanqing, Liao, Bin-Chi, Lou, Yan Yan, Luft, Alexander, Ma, Shaohua, Majem Tarruella, Margarita, Makles, Krytsyna, Martinengo, Gaston, Martinez Marti, Alex, Matias, Danielli, Mazieres, Julien, Molina, Julian, Muto, Satoshi, Nadal Alforja, Ernest, Nesterova, Alfiya, Novello, Silvia, O'Brien, Mary, Ogliari, Francesca, Pastor, Andrea, Pollock, Theodore, Reinacher-Schick, Anke, Ritgen, Mathias, Ruff, Paul, Saji, Hisashi, Sardenberg, Rodrigo, Scheusan, Roxana, Serke, Monika, Shio, Yutaka, Siegel, Robert, Sokur, Iryna, Stencel, Katarzyna, Sugio, Kenji, Suzuki, Hiroyuki, Takamochi, Kazuya, Tan, Lijie, Tatangelo, Marcelo, Thiberville, Luc, Tsai, Chen-Liang, Ungureanu, Andrei, Vansteenkiste, Johan, Wang, Wenxiang, Wirtz, Hubert, Wong, Mark, Yang, Yue, Zhang, Lanjun

“…At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free…”
Get full text

Combined PD-1 and HER2 blockade for HER2-positive gastric cancer by Janjigian, Yelena Y., Kawazoe, Akihito, Yañez, Patricio, Li, Ning, Lonardi, Sara, Kolesnik, Oleksii, Barajas, Olga, Bai, Yuxian, Shen, Lin, Tang, Yong, Wyrwicz, Lucjan S., Xu, Jianming, Shitara, Kohei, Qin, Shukui, Van Cutsem, Eric, Tabernero, Josep, Li, Lie, Shah, Sukrut, Bhagia, Pooja, Chung, Hyun Cheol

“…Human epidermal growth factor receptor 2 ( ERBB2 /HER2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastroesophageal…”
Get full text

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study by Janjigian, Yelena Y., Kawazoe, Akihito, Yanez, Patricio Eduardo, Luo, Suxia, Lonardi, Sara, Kolesnik, Oleksii, Barajas, Olga, Bai, Yuxian, Shen, Lin, Tang, Yong, Wyrwicz, Lucjan, Shitara, Kohei, Qin, Shukui, Van Cutsem, Eric, Tabernero, Josep, Li, Lie, Shih, Chie-Schin, Bhagia, Pooja, Chung, Hyun Cheol Cheol

“…Abstract only 4013 Background: Trastuzumab (tras) plus chemotherapy (chemo) is standard-of-care (SOC) 1L therapy for HER2+ metastatic G/GEJ cancer. In two…”
Get full text

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA) by Trukhin, Dmytro, Poddubskaya, Elena, Andric, Zoran, Makharadze, Tamta, Bellala, Ravi Shankar, Charoentum, Chaiyut, Yañez Ruiz, Eduardo P., Fulop, Andrea, Hyder Ali, Irfhan Ali, Syrigos, Kostas, Katgi, Nuran, Lopez Chuken, Yamil Alonso, Rumyana, Ilieva, Reyes-Igama, Jasmin, Costamilan, Rita de Cassia, Del Campo García, Ana, Florez, Amalia, Paravisini, Alexandra, Millan, Susana

“…Background MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin ® ;…”
Get full text

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study by Chen, Likun, Rangel, Jose David Gomez, Cil, Timucin, Li, Xingya, Cicin, Irfan, Shen, Yihong, Liu, Zhihua, Ozyilkan, Ozgur, Igor, Bondarenko, Chen, Jun, Oleksandr, Kostiuk, Chen, Zhendong, Zhang, Helong, Fu, Ziyi, Dong, Qingfeng, Song, Shuqiang, Yu, Jin‐Chen, Zhang, Li, Hryhoriy, Adamchuk, Karaoglu, Aziz, Hryhoriy, Bardakov, Gao, Beili, Oksuzoglu, Berna, Bilir, Cemil, Jordaan, Christa, Hu, Chunhong, Jacobs, Conrad, Tural, Deniz, Erdem, Dilek, Trukhin, Dmytro, Huang, Dongning, Soto, Francisco Alejo Medina, Igor, Galaychuk, Ursol, Grygorii, Liu, Hailong, Harputluoglu, Hakan, Coskun, Hasan Senol, Cinkir, Havva Yesil, Zhang, Helong, Ma, Hu, Zhao, Hui, Zhu, Huili, Cicin, Irfan, Sokur, Iryna, Sinielnikov, Ivan, Oleksandr, Ivashchuk, Fang, Jian, Shi, Jianhua, Tuohayi, Jiazina, Gao, Jinghua, Peng, Jiyong, Rangel, Jose David Gomez, Lira, Jose Luis Martinez, Chen, Jun, Lu, Junguo, Yao, Juntao, Oleh, Kobziev, Oleksandr, Kostiuk, Anna, Kryzhanivska, Chen, Lei, Cai, Li, Zhang, Li, Zhang, Liangming, Chen, Likun, Syvak, Liubov, Jiang, Liyan, Dupper, Louis, Dreosti, Lydia, Gumus, Mahmut, Artac, Mehmet, Kaplan, Muhammet, Lisovska, Natalya, Kolesnik, Oleksii, Olmez, Omer, Altundag, Ozden, Tanriverdi, Ozgur, Olga, Ponomarova, Li, Qi, Yu, Qitao, Mendoza, Rene Lazaro Gonzalez, Andriy, Rusyn, Wang, Senming, Xu, Shen, Shou, Tao, Yi, Tienan, Cil, Timucin, Li, Wei, Guo, Weidong, Zhao, Weiqing, Yao, Wenxiu, Li, Xingya, Zhao, Yanqiu, Shparyk, Yaroslav, Hotko, Yevhen, Shen, Yihong, Zhang, Yiping, Zheng, Zhendong, Wu, Zhengdong, Liu, Zhihua, Wang, Ziping

“…Background BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference…”
Get full text